[EN] SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3- DIOXYGENASE [FR] N-HYDROXYAMIDINOHÉTÉROCYCLES SUBSTITUÉS EN TANT QUE MODULATEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE
[EN] SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3- DIOXYGENASE [FR] N-HYDROXYAMIDINOHÉTÉROCYCLES SUBSTITUÉS EN TANT QUE MODULATEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE
Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
申请人:PHENEX DISCOVERY VERWALTUNGS-GMBH
公开号:US11078168B2
公开(公告)日:2021-08-03
The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.
Horner,L. et al., Chemische Berichte, 1960, vol. 93, p. 1774 - 1781
作者:Horner,L. et al.
DOI:——
日期:——
SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3- DIOXYGENASE
申请人:Phenex Discovery Verwaltungs-GmbH
公开号:EP3535259A1
公开(公告)日:2019-09-11
SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
申请人:PHENEX DISCOVERY VERWALTUNGS-GMBH
公开号:US20190292160A1
公开(公告)日:2019-09-26
The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.
[EN] SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3- DIOXYGENASE<br/>[FR] N-HYDROXYAMIDINOHÉTÉROCYCLES SUBSTITUÉS EN TANT QUE MODULATEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE
申请人:PHENEX DISCOVERY VERWALTUNGS GMBH
公开号:WO2018083241A1
公开(公告)日:2018-05-11
The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.